Webinar Summary
- Learn about regulation of drug metabolism enzymes and their role in clinically relevant drug-drug and drug-nutrient interactions.
- Hear about tools available to address specific mechanisms governing pharmacokinetics of drugs with an emphasis on cell-based nuclear receptor assays.
- Understand how these cell-based screening assays can be used to address species differences in the drug response.
Drug-drug interactions (DDI) are a cause of many adverse outcomes clinically, costing the health care system over a billion dollars. Thus, there is increasing interest in understanding the risk posed by certain drug candidates early in the discovery process. Fortunately, many aspects of DDI are predictable based on our increasing understanding of the mechanisms of altered absorption, distribution, metabolism, and excretion (ADME) and improved tools for screening for potential liabilities early in the drug-discovery process. These tools include in vitro assays that look at pharmacokinetic interactions through changing the activity of enzymes involved in the clearance of drugs, such as cytochromes P450 (CYPs).
Register for this webinar to learn about the various drug screening and gene expression assays that are available for identifying potential DDI in vitro. We will also discuss crucial CYPs to consider for a gene expression study, and how adding in vitro assays to your workflow to prioritize drug candidates can save time and money lost from pursuing candidates that may fail in animal or clinical trials. Also learn how the data from these in vitro assays can be used for species extrapolation of pharmacokinetic interactions for common laboratory animal models.
Presenters
Jack Vanden Heuvel
Dr. Vanden Heuvel is a recognized expert in the field of nuclear receptor biology and toxicology with over 100 peer-reviewed publications. In addition to his role as Founder and Chief Scientific Officer at INDIGO Biosciences, Dr. Vanden Heuvel is a Professor of Molecular Toxicology at Penn State University.
Sponsor
INDIGO Biosciences
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
